SEL1L-HRD1 ER-associated degradation suppresses hepatocyte hyperproliferation and liver cancer

• DOI: 10.1016/j.isci.2022.105183
• Publication Date: 2022-09-24T06:39:48Z
• Authors: Asmita Bhattacharya; Juncheng Wei; Wenxin Song; Beixue Gao; Chunyan Tian; Shuangcheng Alivi...; Jian Wang; Ligong Chen; Deyu Fang; Ling Qi
• Keywords: Cell biology; 0303 health sciences; 03 medical and health sciences; Molecular biology; Science; Q; Article; Cancer; 3. Good health

Endoplasmic reticulum (ER) homeostasis has been implicated in the pathogenesis of various forms of cancer; however, our understanding of the role of ER quality control mechanisms in tumorigenesis remains incomplete. Here, we show that the SEL1L-HRD1 complex of ER-associated degradation (ERAD) suppresses hepatocyte proliferation and tumorigenesis in mice. Hepatocyte-specific deletion of Sel1L or Hrd1 predisposed mice to diet/chemical-induced tumors. Proteomics screen from SEL1L-deficient livers revealed WNT5A, a tumor suppressor, as an ERAD substrate. Indeed, nascent WNT5A was misfolding prone and degraded by SEL1L-HRD1 ERAD in a quality control capacity. In the absence of ERAD, WNT5A misfolds is largely retained in the ER and forms high-molecular weight aggregates, thereby depicting a loss-of-function effect and attenuating WNT5A-mediated suppression of hepatocyte proliferation. In humans, SEL1L-HRD1 ERAD expression correlated positively with survival time for patients with liver cancer. Overall, our data reveal a key role of SEL1L-HRD1 ERAD in suppressing hepatocyte proliferation and liver cancer.